Nov 01, 2023 / 08:30PM GMT
Operator
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics Webcast Presentation of Interim Safety and Efficacy Data from the Phase I/II AEROW Clinical Trial of Aerosolized 4D-710 for the treatment of cystic fibrosis lung disease. (Operator Instructions) As a reminder, today's call is being recorded.
With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.
Uneek Mehra - 4D Molecular Therapeutics, Inc. - Chief Financial & Business Officer
Thank you, operator, and welcome, everyone, to our webcast. A press release describing the results and development plans related to 4D-710 is accessible in the Investors section of the 4DMT website, and a recording of this webcast will also be accessible on our website after the completion of this call.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer, who will provide introductory remarks. Dr. Alan Cohen, who recently joined 4DMT as SVP, Therapeutic Area Head of
4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call Transcript
Nov 02, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers